Main Article Content
to, improve bioavailability and reduce dosing regimen. Microspheres were prepared by spray drying and cross-linking
method using chitosan and HPMC K4M, using 32 central composite design. Microspheres were evaluated for particle
size, drug content, swelling ability, and percentage yield. Compatibility was checked by doing Fourier transform infrared
spectroscopy and Differential scanning calorimetry study. The polymorphism and particle shape were studied by X-ray
diffraction and scanning electron microscopy. The average particle size of spray-dried and cross-linked formulations were
found in the range between 20-50 Î¼m and 30-60 Î¼m with percent mucoadhesion in the range of 80%-90% and 60-70%,
respectively. In vitro drug release was found to be proportional to drug to polymer ratio. In vitro drug release for optimized
formulation, that is, (F1), for spray-drying method and cross-linking method was found to be 88.73% and 70.93% at the
end of 6 h, respectively. Release of drug from microspheres followed non-Fickian diffusion kinetics. Ex vivo studies were
performed with sheep nasal mucosa for mucoadhesion, histopathological study, and drug permeation. The histopathological study indicates nonirritant nature of microsphere. The microspheres were found to be stable at accelerated storage conditions for 1 month, as per International Conference of Harmonisation guidelines.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
Kaurav H, Harikumar SL, Kaur A. Mucoadhesive microspheres as carriers
in drug delivery: A review. Int J Drug Develop Res 2012;4:21-34.
Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K. Antifibrotic
activities of pirfenidone in animal models. Eur Respir Rev 2011;20:85-97.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D,
et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic
pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet
MacÃas-BarragÃ¡n J, Sandoval-RodrÃguez A, Navarro-Partida J, ArmendÃ¡riz-
Borunda J. The multifaceted role of pirfenidone and its novel targets.
Fibrogenesis Tissue Repair 2010;3:16.
Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic
pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results
of a prospective, open-label phase II study. Am J Respir Crit Care Med
Rathananand M, Kumar DS, Shirwaikar A, Kumar R, Kumar DS, Prasad RS.
Preparation of mucoadhesive microspheres for nasal delivery by spray
drying. Indian J Pharm Sci 2007;69:651-7.
Tadwee Imran AK, Shahi SR, Thube MW, Shaikh AM,
Tribhuwan SD, Mahajan HS. Spray dried nasal mucoadhesive
microspheres of carbamazepine: Preparation and In vitro/Ex vivo
evaluation. Res Pharmaceutica 2011;2:23-32.
Shahi SR, Tribhuwan SD, Tadwee Imran AK, Gupta SK, Zadbuke NS,
Shivanikar SS. Formulation of atenolol mucoadhesive microspheres
for nasal delivery by spray drying technique: In vitro/Ex vivo evaluation.
Der Pharmacia Sinica 2011;2:54-63.
Das MK, Senapati PC. Furosemide-loaded alginate microspheres
prepared by ionic cross-linking technique: Morphology and release
characteristics. Indian J Pharm Sci 2008;70:77-84.
Patel VR, Patel S, Tank HM, Jobanputra C, Brahma D. Formulate and
evaluate the mucoadhesive microsphere of HMG co-A reductase
inhibitor for the treatment of hyperlipidemia. Int J Pharm Res Bio Sci
Jain SK, Jain NK, Gupta Y, Jain A, Jain D, Chaurasia M. Mucoadhesive
chitosan microspheres for non-invasive and improved nasal delivery
of insulin. Indian J Pharm Sci 2007;69:498-504.
Yadav AV, Mote HH. Development of biodegradable starch microspheres
for intranasal delivery. Indian J Pharm Sci 2008;70:170-4.